Amphastar Pharmaceuticals (AMPH) Net Profit Margin: History & Chart

Amphastar Pharmaceuticals, Inc.(AMPH)

Drug Manufacturers - Specialty & Generic · Rancho Cucamonga, CA

$25.56+0.19 (+0.75%)

Delayed quote: Oct 6, 2026, 12:10 PM EDT

About Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.

Rancho Cucamonga, CA

1,976 employees

www.amphastar.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Yongfeng Zhang

View full financials

AMPH Net Profit Margin Metrics

NET PROFIT MARGIN

10.76%

NET PROFIT MARGIN AVG TTM

12.09%

NET PROFIT MARGIN AVG 3Y

18.73%

NET PROFIT MARGIN AVG 5Y

18.31%

NET PROFIT MARGIN AVG 10Y

9.67%

NET PROFIT MARGIN AVG 15Y

N/A

NET PROFIT MARGIN AVG 20Y

N/A

CURRENT VS TTM AVG

-10.97%

CURRENT VS 3Y AVG

-42.54%

CURRENT VS 5Y AVG

-41.22%

CURRENT VS 10Y AVG

+11.22%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

0.00%

median of 724 covered companies

CURRENT VS SECTOR MEDIAN

N/A

vs the sector median at left

NAME	MARKET CAP	NET PROFIT MARGIN	TTM	3Y	5Y
Amphastar Pharmaceuticals, Inc. (AMPH)	$1.13B	10.76%	12.09%	18.73%	18.31%
Harrow Health, Inc. (HROW)vs ›	$1.14B	-13.51%	-5.33%	-11.32%	-12.84%
Replimune Group, Inc. (REPL)vs ›	$1.11B	0.00%	0.00%	0.00%	0.00%
OPKO Health, Inc. (OPK)vs ›	$1.13B	-12.40%	-22.32%	-24.80%	-16.46%
Avalyn Pharma Inc. Common Stock (AVLN)vs ›	$1.14B	0.00%	0.00%	0.00%	0.00%
GoodRx Holdings, Inc. (GDRX)vs ›	$1.15B	2.07%	2.94%	0.11%	-9.38%
Bicara Therapeutics Inc. Common Stock (BCAX)vs ›	$1.09B	0.00%	0.00%	0.00%	0.00%
Nektar Therapeutics (NKTR)vs ›	$1.15B	-287.84%	-208.97%	-281.06%	-321.48%
IRadimed Corporation (IRMD)vs ›	$1.09B	26.70%	26.54%	25.84%	21.67%
Damora Therapeutics, Inc. (DMRA)vs ›	$1.17B	0.00%	0.00%	0.00%	0.00%

NAME

MARKET CAP

NET PROFIT MARGIN

TTM

Amphastar Pharmaceuticals, Inc. (AMPH)

$1.13B

10.76%

12.09%

18.73%

18.31%

Harrow Health, Inc. (HROW)vs ›

$1.14B

-13.51%

-5.33%

-11.32%

-12.84%

Replimune Group, Inc. (REPL)vs ›

$1.11B

0.00%

OPKO Health, Inc. (OPK)vs ›

$1.13B

-12.40%

-22.32%

-24.80%

-16.46%

Avalyn Pharma Inc. Common Stock (AVLN)vs ›

$1.14B

0.00%

GoodRx Holdings, Inc. (GDRX)vs ›

$1.15B

2.07%

2.94%

0.11%

-9.38%

Bicara Therapeutics Inc. Common Stock (BCAX)vs ›

$1.09B

0.00%

Nektar Therapeutics (NKTR)vs ›

$1.15B

-287.84%

-208.97%

-281.06%

-321.48%

IRadimed Corporation (IRMD)vs ›

$1.09B

26.70%

26.54%

25.84%

21.67%

Damora Therapeutics, Inc. (DMRA)vs ›

$1.17B

0.00%

Net Profit Margin FAQ

What is the net profit margin for Amphastar Pharmaceuticals, Inc. (AMPH)?

The net profit margin for AMPH stock is 10.76%.

Is Amphastar Pharmaceuticals, Inc.'s net profit margin high or low?

The net profit margin of 10.76% is 41% below its 5-year average of 18.31%, near the low end of its 5-year range (3.75%–27.26%).

What is the TTM average net profit margin for Amphastar Pharmaceuticals, Inc. (AMPH)?

The TTM average net profit margin for AMPH stock is 12.09%.

What is the 3Y average net profit margin for Amphastar Pharmaceuticals, Inc. (AMPH)?

The 3Y average net profit margin for AMPH stock is 18.73%.

What is the 5Y average net profit margin for Amphastar Pharmaceuticals, Inc. (AMPH)?

The 5Y average net profit margin for AMPH stock is 18.31%.

What is the 10Y average net profit margin for Amphastar Pharmaceuticals, Inc. (AMPH)?

The 10Y average net profit margin for AMPH stock is 9.67%.

DATE	NET PROFIT MARGIN
2026-06-30	16.50%
2026-03-31	3.75%
2025-12-31	13.34%
2025-09-30	9.04%
2025-06-30	17.79%
2025-03-31	14.83%
2024-12-31	20.35%
2024-09-30	21.41%
2024-06-30	20.81%
2024-03-31	25.13%
2023-12-31	20.31%
2023-09-30	27.26%
2023-06-30	17.93%
2023-03-31	18.59%
2022-12-31	25.12%
2022-09-30	13.21%
2022-06-30	14.05%
2022-03-31	20.15%
2021-12-31	16.35%
2021-09-30	26.34%
2021-06-30	7.64%
2021-03-31	4.89%
2020-12-31	-6.54%
2020-09-30	4.70%
2020-06-30	-0.22%
2020-03-31	4.66%
2019-12-31	-1.23%
2019-09-30	1.63%
2019-06-30	60.45%
2019-03-31	1.09%
2018-12-31	2.08%
2018-09-30	3.16%
2018-06-30	-3.93%
2018-03-31	-12.41%
2017-12-31	2.43%
2017-09-30	0.30%
2017-06-30	3.03%
2017-03-31	1.58%
2016-12-31	-4.32%
2016-09-30	6.06%
2016-06-30	10.13%
2016-03-31	4.19%
2015-12-31	9.79%
2015-09-30	-4.71%
2015-06-30	-12.34%
2015-03-31	-1.17%
2014-12-31	-4.51%
2014-09-30	-9.01%
2014-06-30	-2.41%
2014-03-31	-3.53%
2013-12-31	3.33%
2013-09-30	-0.27%
2013-06-30	12.49%
2013-03-31	4.50%
2012-12-31	8.38%

DATE

NET PROFIT MARGIN

2026-06-30

16.50%

2026-03-31

3.75%

2025-12-31

13.34%

2025-09-30

9.04%

2025-06-30

17.79%

2025-03-31

14.83%

2024-12-31

20.35%

2024-09-30

21.41%

2024-06-30

20.81%

2024-03-31

25.13%

2023-12-31

20.31%

2023-09-30

27.26%

2023-06-30

17.93%

2023-03-31

18.59%

2022-12-31

25.12%

2022-09-30

13.21%

2022-06-30

14.05%

2022-03-31

20.15%

2021-12-31

16.35%

2021-09-30

26.34%

2021-06-30

7.64%

2021-03-31

4.89%

2020-12-31

-6.54%

2020-09-30

4.70%

2020-06-30

-0.22%

2020-03-31

4.66%

2019-12-31

-1.23%

2019-09-30

1.63%

2019-06-30

60.45%

2019-03-31

1.09%

2018-12-31

2.08%

2018-09-30

3.16%

2018-06-30

-3.93%

2018-03-31

-12.41%

2017-12-31

2.43%

2017-09-30

0.30%

2017-06-30

3.03%

2017-03-31

1.58%

2016-12-31

-4.32%

2016-09-30

6.06%

2016-06-30

10.13%

2016-03-31

4.19%

2015-12-31

9.79%

2015-09-30

-4.71%

2015-06-30

-12.34%

2015-03-31

-1.17%

2014-12-31

-4.51%

2014-09-30

-9.01%

2014-06-30

-2.41%

2014-03-31

-3.53%

2013-12-31

3.33%

2013-09-30

-0.27%

2013-06-30

12.49%

2013-03-31

4.50%

2012-12-31

8.38%

Net Profit Margin: 10.76%

AMPH Profit Margin

AMPH Average Net Profit Margin Chart

AMPH Current vs Average Net Profit Margin Chart

AMPH Net Profit Margin Metrics

AMPH Competitors' Net Profit Margin

Margin Comparison

Net Profit Margin Formula & Definition

Net Profit Margin FAQ

AMPH Net Profit Margin History

Related Metrics